Physician altruism and moral hazard: (no) Evidence from Finnish national prescriptions data.


Journal

Journal of health economics
ISSN: 1879-1646
Titre abrégé: J Health Econ
Pays: Netherlands
ID NLM: 8410622

Informations de publication

Date de publication:
05 2019
Historique:
received: 05 08 2017
revised: 02 12 2018
accepted: 16 03 2019
pubmed: 26 4 2019
medline: 20 8 2020
entrez: 26 4 2019
Statut: ppublish

Résumé

We test the physicians' altruism and moral hazard hypotheses using a national panel register containing all 2003-2010 statins prescriptions in Finland. We estimate the likelihood that physicians prescribe generic versus branded versions of statins as a function of the shares of the difference between what patients have to pay out of their pocket and what is covered by the insurance, controlling for patient, physician, and drug characteristics. We find that the estimated coefficients and the average marginal effects associated with moral hazard and altruism are nearly zero, and are orders of magnitude smaller than the ones associated with other explanatory factors such as the prescriptions' year and the physician specialization. When the analysis distinctly accounts for both the patient and the insurer shares of expenditure, the estimated coefficients directly reject the altruism and moral hazard hypotheses. Instead, we find strong and robust evidence of habits persistence in prescribing branded drugs.

Identifiants

pubmed: 31022628
pii: S0167-6296(17)30734-8
doi: 10.1016/j.jhealeco.2019.03.006
pii:
doi:

Substances chimiques

Drugs, Generic 0
Hydroxymethylglutaryl-CoA Reductase Inhibitors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

153-169

Informations de copyright

Copyright © 2019. Published by Elsevier B.V.

Auteurs

Giovanni Crea (G)

University of Pavia, Department of Economics and Management, Italy. Electronic address: giovanni.crea@unipv.it.

Matteo M Galizzi (MM)

London School of Economics, Department of Psychological and Behavioural Science, LSE Global Health Initiative, LSE Behavioural Science Hub, Room 3.16, Queens House, 55/56 Lincoln's Inn Fields, WC2A 3LJ, London, UK; Paris School of Economics - École d'Économie de Paris, Hospinnomics, Hôtel-Dieu, 1, Parvis de Notre-Dame, Bâtiment B1, 5° étage, 75004, Paris, France. Electronic address: m.m.galizzi@lse.ac.uk.

Ismo Linnosmaa (I)

National Institute for Health and Welfare, Centre for Health and Social Economics, Mannerheimintie 166, 00271, Helsinki, Finland; University of Eastern Finland, Department of Social and Health Management, Yliopistonranta 1E, Snellmania Building, 70211, Kuopio, Finland. Electronic address: ismo.linnosmaa@thl.fi.

Marisa Miraldo (M)

Paris School of Economics - École d'Économie de Paris, Hospinnomics, Hôtel-Dieu, 1, Parvis de Notre-Dame, Bâtiment B1, 5° étage, 75004, Paris, France; Imperial College Business School, Department of Management & Centre for Health Economics & Policy Innovation (CHEPI), South Kensington Campus, SW7 2AZ, London, UK. Electronic address: m.miraldo@imperial.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH